Aaron Lisberg, MD

Research Summary:

Dr. Lisberg conducts translational research on novel therapeutic approaches in advanced malignancies, with a specific focus on lung cancer. He has a wide range of ongoing research projects including evaluation of factors predictive of response or toxicity to antibody drug conjugates (ADCs) and immune checkpoint inhibitors, pre-clinical/clinical evaluation of novel metabolic therapies, and assessment of effective treatments in patients with targetable tumor alterations. He is also the clinical PI and Sub-I of several clinical trials evaluating novel therapeutics in a variety of malignancies, including Phase I, II, and III assessments.

Link to a complete list of publications for Dr. Lisberg

Brief summary of publications, as follows:

1. Velez MA, Tsai HHC, Shackelford DB, Garon EB, Lisberg A. What is the current role of immunotherapy in EGFR mutant advanced NSCLC?. Lung Cancer. 2022 Apr;166:253-254. doi: 10.1016/j.lungcan.2021.12.001. Epub 2021 Dec 24. PubMed PMID: 35031176.
2. Zhou N, Velez MA, Bachrach B, Gukasyan J, Fares CM, Cummings AL, Lind-Lebuffe JP, Akingbemi WO, Li DY, Brodrick PM, Yessuf NM, Rettinger S, Grogan T, Rochigneux P, Goldman JW, Garon EB, Lisberg A. Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC. Lung Cancer. 2021 Nov;161:34-41. doi: 10.1016/j.lungcan.2021.08.009. Epub 2021 Aug 30. PubMed PMID: 34507111; PubMed Central PMCID: PMC8923054.
3. Lisberg A, Cummings A, Goldman JW, Bornazyan K, Reese N, Wang T, Coluzzi P, Ledezma B, Mendenhall M, Hunt J, Wolf B, Jones B, Madrigal J, Horton J, Spiegel M, Carroll J, Gukasyan J, Williams T, Sauer L, Wells C, Hardy A, Linares P, Lim C, Ma L, Adame C, Garon EB. A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC. J Thorac Oncol. 2018 Aug;13(8):1138-1145. doi: 10.1016/j.jtho.2018.03.035. Epub 2018 Jun 1. PubMed PMID: 29874546; PubMed Central PMCID: PMC6063769.
4. Lisberg A, Tucker DA, Goldman JW, Wolf B, Carroll J, Hardy A, Morris K, Linares P, Adame C, Spiegel ML, Wells C, McKenzie J, Ledezma B, Mendenhall M, Abarca P, Bornazyan K, Hunt J, Moghadam N, Chong N, Nameth D, Marx C, Madrigal J, Vangala S, Shaverdian N, Elashoff D, Garon EB. Treatment-Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center. Cancer Immunol Res. 2018 Mar;6(3):288-294. doi: 10.1158/2326-6066.CIR-17-0063. Epub 2018 Jan 30. PubMed PMID: 29382669; PubMed Central PMCID: PMC6066474.
5. Shaverdian N, Lisberg AE, Bornazyan K, Veruttipong D, Goldman JW, Formenti SC, Garon EB, Lee P. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol. 2017 Jul;18(7):895-903. doi: 10.1016/S1470-2045(17)30380-7. Epub 2017 May 24. PubMed PMID: 28551359; PubMed Central PMCID: PMC5538772.
6. Zhou N, Velez MA, Owen D, Lisberg AE. Immune-Related Adverse Events (irAEs): Implications for Immune Checkpoint Inhibitor Therapy. J Natl Compr Canc Netw. 2020 Sep;18(9):1287-1290. doi: 10.6004/jnccn.2020.7640. PubMed PMID: 32886906. 
7. Hu-Lieskovan S, Lisberg A, Zaretsky JM, Grogan TR, Rizvi H, Wells DK, Carroll J, Cummings A, Madrigal J, Jones B, Gukasyan J, Shintaku IP, Slamon D, Dubinett S, Goldman JW, Elashoff D, Hellmann MD, Ribas A, Garon EB. Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non-Small Cell Lung Cancer. Clin Cancer Res. 2019 Aug 15;25(16):5061-5068. doi: 10.1158/1078-0432.CCR-18-4275. Epub 2019 May 21. PubMed PMID: 31113840; PubMed Central PMCID: PMC6901027. 
8. Lisberg A, Garon EB. The Value of PD-L1 Testing in Non-Small-Cell Lung Cancer. JAMA Oncol. 2016 May 1;2(5):571-572. doi: 10.1001/jamaoncol.2016.0043. PubMed PMID: 26986923.
9. Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, Reyes M, Lenvik T, Lund T, Blackstad M, Du J, Aldrich S, Lisberg A, Low WC, Largaespada DA, Verfaillie CM. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature. 2002 Jul 4;418(6893):41-9. doi: 10.1038/nature00870. Epub 2002 Jun 20. PubMed PMID: 12077603.
10. Lisberg A, Garon EB. Does Platinum-Based Chemotherapy Still Have a Role in First-Line Treatment of Advanced Non-Small-Cell Lung Cancer?. J Clin Oncol. 2019 Mar 1;37(7):529-536. doi: 10.1200/JCO.18.01534. Epub 2019 Jan 24. PubMed PMID: 30676857.

• uclahealth.org/community-cancercare
• uclahealth.org/community-cancercare/smoncology2020